When given the option to prolong hormone-based breast cancer treatment, many patients chose to, new research finds.

A new study led by University of Michigan Health Rogel Cancer Center and Stanford Medicine scientists concluded:

·       Nearly half of early-stage breast cancer patients (47%) decided to extend their treatment to 10 years after finishing five.

·       62% of stage 2 patients said they would extend their treatment.

·       39% of stage 1 patients were willing to prolong treatment.

·       Physician recommendation was a deciding factor for many women.

·       Fear of recurrence was also a deciding factor.